Mayo Clinic News Network

News Resources

Items tagged as "rituximab"

Lymphoma Patients Event-Free Two Years after Diagnosis have a Normal Life Expectancy

Lymphoma Patients Event-Free Two Years after Diagnosis have a Normal Life Expectancy

http://www.youtube.com/watch?v=8jwdHjAnJCM ROCHESTER, Minn. — Feb. 18, 2014 — Newly-diagnosed patients with diffuse large B cell lymphoma (DLBCL) who do not experience any cancer-related outcome events for two years after diagnosis have essentially the same life expectancy as they did prior to diagnosis, a Mayo Clinic study has found. Cancer related [...]

Created by Joe Dangor

Specks What study means for patients (:38)

Mayo Clinic pulmonologist Ulrich Specks, M.D., discusses a study by Mayo Clinic and others that found the drug rituximab effective for ANCA-associated vasculitis. Mayo Clinic is part of the Vasculitis Clinical Research Consortium , a National Institutes of Health-funded effort investigating inflammatory blood vessel disorders.

Created by Brian Kilen

Specks Rituximab and vasculitis relapses (:35)

Mayo Clinic pulmonologist Ulrich Specks, M.D., discusses a study by Mayo Clinic and others that found the drug rituximab effective for ANCA-associated vasculitis. Mayo Clinic is part of the Vasculitis Clinical Research Consortium, a National Institutes of Health-funded effort investigating inflammatory blood vessel disorders.

Created by Brian Kilen

Specks What vasculitis-rituximab study found (1:10)

Mayo Clinic pulmonologist Ulrich Specks, M.D., discusses a study by Mayo Clinic and others that found the drug rituximab effective for ANCA-associated vasculitis. Mayo Clinic is part of the Vasculitis Clinical Research Consortium, a National Institutes of Health-funded effort investigating inflammatory blood vessel disorders.

Created by Brian Kilen

Specks What is next (:52)

Dr. Ulrich Specks describes a study on rituximab and vasculitis.

Created by Brian Kilen

Load More